178 related articles for article (PubMed ID: 35983808)
1. Post-Finasteride Syndrome. Literature Review.
Romero Pérez P
Arch Esp Urol; 2022 Jun; 75(5):382-399. PubMed ID: 35983808
[TBL] [Abstract][Full Text] [Related]
2. Post-finasteride syndrome: a surmountable challenge for clinicians.
Traish AM
Fertil Steril; 2020 Jan; 113(1):21-50. PubMed ID: 32033719
[TBL] [Abstract][Full Text] [Related]
3. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia.
Chiriacò G; Cauci S; Mazzon G; Trombetta C
Andrology; 2016 Mar; 4(2):245-50. PubMed ID: 26763726
[TBL] [Abstract][Full Text] [Related]
4. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.
Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z
J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature.
Busetto GM; Del Giudice F; D'Agostino D; Romagnoli D; Minervini A; Rocco B; Antonelli A; Celia A; Schiavina R; Cindolo L; Chung BI; Kim JH; Maggi M; Sciarra A; De Berardinis E; Porreca A
Arch Ital Urol Androl; 2020 Jan; 91(4):205-210. PubMed ID: 31937082
[TBL] [Abstract][Full Text] [Related]
6. Post-finasteride syndrome - does it really exist?
Maksym RB; Kajdy A; Rabijewski M
Aging Male; 2019 Dec; 22(4):250-259. PubMed ID: 30651009
[TBL] [Abstract][Full Text] [Related]
7. Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men.
Walf AA; Kaurejo S; Frye CA
Am J Mens Health; 2018 Jul; 12(4):900-906. PubMed ID: 29318957
[TBL] [Abstract][Full Text] [Related]
8. Guidelines on the use of finasteride in androgenetic alopecia.
Mysore V; Shashikumar BM
Indian J Dermatol Venereol Leprol; 2016; 82(2):128-34. PubMed ID: 26924401
[TBL] [Abstract][Full Text] [Related]
9. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
[TBL] [Abstract][Full Text] [Related]
10. Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
Gupta MA; Vujcic B; Gupta AK
Skinmed; 2020; 18(3):146-150. PubMed ID: 32790610
[TBL] [Abstract][Full Text] [Related]
11. [Finasteride adverse effects: An update].
Carreño-Orellana N; Moll-Manzur C; Carrasco-Zuber JE; Álvarez-Véliz S; Berroeta-Mauriziano D; Porras-Kusmanic N
Rev Med Chil; 2016 Dec; 144(12):1584-1590. PubMed ID: 28393993
[TBL] [Abstract][Full Text] [Related]
12. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
Arias-Santiago S; Camacho-Martínez FM
Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801
[No Abstract] [Full Text] [Related]
13. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
14. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date.
Iamsumang W; Leerunyakul K; Suchonwanit P
Drug Des Devel Ther; 2020; 14():951-959. PubMed ID: 32184564
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
[TBL] [Abstract][Full Text] [Related]
16. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.
Cecchin E; De Mattia E; Mazzon G; Cauci S; Trombetta C; Toffoli G
Int J Biol Markers; 2014 Dec; 29(4):e310-6. PubMed ID: 24855036
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
[TBL] [Abstract][Full Text] [Related]
18. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature.
Suchonwanit P; Iamsumang W; Leerunyakul K
J Dermatolog Treat; 2022 Mar; 33(2):643-648. PubMed ID: 32538225
[TBL] [Abstract][Full Text] [Related]
19. Safety Profile of Finasteride: Distribution of Adverse Effects According to Structural and Informational Dichotomies of the Mind/Brain.
Motofei IG; Rowland DL; Manea M; Georgescu SR; Păunică I; Sinescu I
Clin Drug Investig; 2017 Jun; 37(6):511-517. PubMed ID: 28161756
[TBL] [Abstract][Full Text] [Related]
20. Dutasteride in Androgenetic Alopecia: An Update.
Arif T; Dorjay K; Adil M; Sami M
Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
